Clinical and laboratory patterns during immune stimulation in hormone responsive metastatic breast cancer

Biomedicine and Pharmacotherapy

Volumn 68, Issue 2, 2014, Pages 171-178

  Nicolini, Andrea ^a   Rossi, Giuseppe ^b   Ferrari, Paola ^a   Carpi, Angelo ^a  

^a UNIVERSITY OF PISA   (Italy)

^b INSTITUTE OF CLINICAL PHYSIOLOGY   (Italy)

Author keywords

Breast cancer; Cytokines; Distant metastases; Endocrine dependent; Hormone therapy; Immunotherapy

Indexed keywords

ANTHRACYCLINE; BETA INTERFERON; C REACTIVE PROTEIN; CA 15-3 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; ESTROGEN RECEPTOR; FLUOROURACIL; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 6; LETROZOLE; MELATONIN; NAVELBINE; PROGESTERONE RECEPTOR; RECOMBINANT INTERLEUKIN 2; TAMOXIFEN; TAXANE DERIVATIVE; TOREMIFENE; TRANSFORMING GROWTH FACTOR BETA1; TUMOR MARKER; TUMOR NECROSIS FACTOR ALPHA;

ADD ON THERAPY; ADULT; AGED; ARTICLE; BREAST METASTASIS; CANCER IMMUNOTHERAPY; CD4 LYMPHOCYTE COUNT; CD4+ CD25+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CLINICAL ARTICLE; DISEASE COURSE; DRUG DOSE INCREASE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HORMONE RESISTANCE; HUMAN; IMMUNOCOMPETENT CELL; IMMUNOSTIMULATION; MIDDLE AGED; NATURAL KILLER CELL; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; STATISTICAL SIGNIFICANCE; VERY ELDERLY;

BREAST CANCER; CYTOKINES; DISTANT METASTASES; ENDOCRINE DEPENDENT; HORMONE THERAPY; IMMUNOTHERAPY;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CARCINOEMBRYONIC ANTIGEN; CYTOKINES; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; IMMUNITY, CELLULAR; IMMUNOTHERAPY; INTERFERON-BETA; INTERLEUKIN-2; MIDDLE AGED; MUCIN-1; NEOPLASM METASTASIS; NEOPLASMS, HORMONE-DEPENDENT; NITRILES; PROPORTIONAL HAZARDS MODELS; SELECTIVE ESTROGEN RECEPTOR MODULATORS; T-LYMPHOCYTES; TAMOXIFEN; TISSUE POLYPEPTIDE ANTIGEN; TOREMIFENE; TRIAZOLES;

EID: 84897087595     PISSN: 07533322     EISSN: 19506007     Source Type: Journal    
DOI: 10.1016/j.biopha.2013.11.005     Document Type: Article

References (27)

1. Nicolini A., Carpi A. Beta-interferon and interleukin-2 prolong more than three times the survival of 26 consecutive endocrine dependent breast cancer patients with distant metastases: an exploratory trial. Biomed Pharmacother 2005, 59:253-263.
2. Nicolini A., Carpi A., Rossi G. An immunotherapy schedule in endocrine-dependent metastatic breast cancer: correlation between clinical course and immunologic parameters. J Immunother 2005, 28:276-279.
3. Nicolini A., Carpi A., Rossi G. Relationship of cellular immunity, cytokines and CRP with clinical course in breast cancer patients with endocrine-dependent distant metastases treated with immunotherapy. Cancer Lett 2007, 251:330-338.
4. Lonning P.E., Bajetta E., Murray R., Tubiana-Hulin M., Eisenberg P.D., Mickiewicz E., et al. Activity of exemestane in metastatic breast cancer after failure of nonsteroidal aromatase inhibitors: a phase II trial. J Clin Oncol 2000, 18:2234-2244.
5. Ladoire S., Martin F., Ghiringhelli F. Prognostic role of FOXP3+ regulatory T cells infiltrating human carcinomas: the paradox of colorectal cancer. Cancer Immunol Immunother 2011, 60:909-918.
6. Rudensky A.Y. Regulatory T cells and Foxp3. Immunol Rev 2011, 241:260-2685.
7. Nicolini A., Carpi A., Ferrari P., Pieri L. Utility of a serum tumour marker panel in the post-operative follow-up of breast cancer patients with equivocal conventional radiological examinations. Tumour Biol 2003, 24:275-280.
8. SPSS 10.0, SPSS Inc., Chicago, Illinois, USA.
9. Weide R., Mergenthaler U., Pandorf A., et al. Improved survival of patients with metastatic breast cancer in routine care: results of a retrospective study in a community-based oncology group practice 1995-2005. Onkologie 2009, 32:107-113.
10. Sledge G.W., Hu P., Falkson G., Tormey D., Abeloff M. Comparison of chemotherapy with chemohormonal therapy as first-line therapy for metastatic, hormone-sensitive breast cancer: an Eastern Cooperative Oncology Group study. J Clin Oncol 2000, 18:262-266.
11. Paridaens R.J., Dirix L.Y., Beex L.V., Nooij M., Cameron D.A., Cufer T., et al. Phase III study comparing exemestane with tamoxifen as first-line hormonal treatment of metastatic breast cancer in postmenopausal women: the European Organisation for Research and Treatment of Cancer Breast Cancer Cooperative Group. J Clin Oncol 2008, 26:4883-4890.
12. Mouridsen H., Gershanovich M., Sun Y., Perez-Carrion R., Boni C., Monnier A., et al. Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: analysis of survival and update of efficacy from the International Letrozole Breast Cancer Group. J Clin Oncol; 2003, 21:2101-2109.
13. Nabholtz J.M., Bonneterre J., Buzdar A., Robertson J.F., Thürlimann B. Anastrozole (Arimidex) versus tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: survival analysis and updated safety results. Eur J Cancer 2003, 39:1684-1689.
14. Colotta F., Allavena P., Sica A., Garlanda C., Mantovani A. Cancer-related inflammation, the seventh hallmark of cancer: links to genetic instability. Carcinogenesis 2009, 30:1073-1081.
15. Lewis C.E., Hughes R. Inflammation and breast cancer. Microenvironmental factors regulating macrophage function in breast tumours: hypoxia and angiopoietin-2. Breast Cancer Res 2007, 9:209.
16. Abbas A.K., Lichtman A.H. Cytokines. Cellular and molecular immunology 2005, Elsevier-Masson, Milan, [chapter 11]. 5th Ed.
17. Nicolini A., Carpi A. Immune manipulation of advanced breast cancer: an interpretative model of the relationship between immune system and tumor cell biology. Med Res Rev 2009, 29:436-471.
18. Yang L., Pang Y., Moses H.L. TGF-beta and immune cells: an important regulatory axis in the tumor microenvironment and progression. Trends Immunol 2010, 31:220-227.
19. Thompson A.M., Kerr D.J., Steel C.M. Transforming growth factor beta 1 is implicated in the failure of tamoxifen therapy in human breast cancer. Br J Cancer 1991, 63(4):609-614.
20. Quezada S.A., Peggs K.S., Simpson T.R., Allison J.P. Shifting the equilibrium in cancer immunoediting: from tumor tolerance to eradication. Immunol Rev 2011, 241(1):104-118.
21. Gennari A., Conte P., Rosso R., Orlandini C., Bruzzi P. Survival of metastatic breast carcinoma patients over a 20-year period: a retrospective analysis based on individual patient data from six consecutive studies. Cancer 2005, 104:1742-1750.
22. Chung C.T., Carlson R.W. Goals and objectives in the management of metastatic breast cancer. Oncologist 2003, 8:514-520.
23. Koizumi M., Yoshimoto M., Kasumi F., Ogata E. Comparison between solitary and multiple skeletal metastatic lesions of breast cancer patients. Ann Oncol 2003, 14:1234-1240.
24. Güth U., Huang D.J., Dirnhofer S., Rochlitz C., Wight E. Distant metastatic breast cancer as an incurable disease: a tenet with a need for revision. Cancer J 2009, 15:81-86.
25. Diaz-Canton E.A., Valero V., Rahman Z., Rodriguez-Monge E., Frye D., Smith T., et al. Clinical course of breast cancer patients with metastases confined to the lungs treated with chemotherapy. The University of Texas M.D. Anderson Cancer Center experience and review of the literature. Ann Oncol 1998, 9:413-418.
26. Arteaga C.L., Koli K.M., Dugger T.C., Clarke R. Reversal of tamoxifen resistance of human breast carcinomas in vivo by neutralizing antibodies to transforming growth factor-beta. J Natl Cancer Inst 1999, 91(1):46-53.
27. Luster M.I., Hayes H.T., Korach K., Tucker A.N., Dean J.H., Greenlee W.F., et al. Estrogen immunosuppression is regulated through estrogenic responses in the thymus. J Immunol 1984, 133(1):110-116.